At least seven arenavirus species including Lassa virus are associated with severe arenavirus hemorrhagic fevers (AHFs) in humans. While there are no approved drugs or vaccines for the treatment of Lassa (or other AHFs) an estimated 300,000 infections and 5000 deaths occur annually from Lassa virus alone. In association with the Defense Threat Reduction Agency (DTRA), Battelle Memorial and the National Institute for Allergy and Infectious Disease (NIAID), Arisan Therapeutics has identified and is currently evaluating ARN-75039 in Phase 1 clinical studies to provide a potent, convenient and urgently needed oral broad-spectrum AHF / Lassa therapeutic.

Filoviruses include a number of Ebolavirus species including Zaire (EBOV), Sudan (SUDV) and Bundibugyo (BDBV), as well the related Marburg virus (MARV), associated with severe human hemorrhagic fevers endemic to Africa, and for which there are currently no approved convenient oral therapeutic treatments. In association with Chemical and Biological Defense Program (CBD) and the National Institute for Allergy and Infectious Disease (NIAID) Arisan identified a chemical series, including a lead compound (ARN-75092) of Ebolavirus inhibitors. Additional discovery efforts have recently identified several novel broad spectrum filovirus chemical series, through structure-based rational drug design and computational chemistry, for optimization and further development.